CSL Announces Robust Immune Response From Single Dose Of Swine Flu Vaccine; TGA Approval Expected Soon
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - CSL Limited announced Sept. 11 that 95 percent of swine flu vaccine clinical trial participants achieved appropriate antibody levels with a single 15 mcg dose of the new Panvax vaccine